We describe a single-run method for quantitating quinidine, procainamide, and N-acetylprocainamide, involving gas-liquid chromatography with a nitrogen-phosphorus selective detector. Within-run precision (CV) was 3% ( = 2 mg/L, n = 20), 6.9% ( = 4 mg/L, n = 10), and 1.5% 
We describe a single-run method for quantitating quinidine, procainamide, and N-acetylprocainamide, involving gas-liquid chromatography with a nitrogen-phosphorus selective detector. Within-run precision (CV) was 3% ( = 2 mg/L, n = 20), 6.9% ( = 4 mg/L, n = 10), and 1.5% ( = 8 mg/L, n = 8)for quinidine; 7.7% ( = 4 mg/L, n = 14), 1.6% (k = 8 mg/L, n = 16), and 2.3% ( = 12 mg/L, n = 12) for procainamide;
and 6.3% ( = 5 mg/L, n = 6), A weak base, it is primarily metabolized by the liver, has an average biological half-life of 6 h in healthy individuals,
has a large volume of distribution, and is highly (80-90%) bound to plasma proteins (1, 2) . The therapeutic concentration range appears to be 2.3-5.0 mgfL (1).
Procainamide is most often administered orally for control of chronic ventricular arrhythmias (2, 3) . Recently, it has also been used intravenously for control of ventricular ectopy in acute ischemia (4). In contrast to quinidine, procainamide has a shorter half-life (3-4 h), is weakly (14-23%) bound to plasma proteins, and has a major renal route of elimination. The therapeutic range is from 3 to 8 or 10 mg/L. Procainamide is also metabolized in the liver to N-acetylprocainamide, a compound with antiarrhythmic activity and a renal elimination route (5).
The role of N-acetylprocainamide in therapeutics is currently under investigation; however, it is already clear that measurements of concentrations in serum are clinically indicated.
These three drugs have been quantitated by spectrophotofluorometry (7, 8), gas chromatography with electroncapture detector (9, 10), and "high-pressure" liquid chro-matography (11). Previous methodology rarely dealt with all three compounds (12). However, the concentrations of any of them in plasma are frequently quantitated in clinical practice; moreover, these drugs are occasionally co-administered to the same patient. Because their separate determination is inconvenient and time consuming, whether for clinical or research purposes, we developed a method for their simultaneous determination in serum by gas chromatography, with use of a nitrogen-phosphorus selective detector.
Materials and Methods
We used a Model 57 bA gas chromatograph, 
Standards:
All standards were dissolved in doubly distilled water. The internal standard was the dipropyl analog of procainamide (E. R. Squibb & Sons, Inc., Princeton, NJ 08540) at 20 g/L. Stock solutions of quinidine sulfate, 50 mgIL, and procainamide hydrochloride, 40 mg/L, both from Sigma Chemical Co., St. Louis, MO 63178, and N-acetylprocainamide (Squibb & Sons, Inc.), 40 mg/L, were stored at 4 #{176}C. These standards and reagents were stable for at least six months.
Operating conditions:
We used nitrogen as the carrier gas with a flow rate of 40 mL/min. The injector-port temperature was 300#{176}C. The detector temperature was 350 #{176}C with an air flow to the detector of 60 mL/min and a hydrogen flow rate of 3.5 mL/min. The oven temperature was programmed to start at 230 #{176}C for 4 mm, then increase at 16 #{176}C/min to a maximum temperature of 280 #{176}C for 4 mm. We applied 15.8 V to the detector. Careful attention to voltages and avoidance of fluctuations in line current are necessary for accurate quantitation.
Procedure: Rinse acid-washed glassware with de-ionized distilled water before use. Add 0.5 mL of serum to a 12-mL glass centrifuge tube and adjust to alkaline pH with 0.25 mL of a 50 g/L NaOH solution. Add 40 pL of the internal standard (the dipropyl derivative of procainamide), vortex-mix, add 2 mL of methylene chloride, and mix again for 2 mm. After centrifugation (600 X g, 5 mm, room temperature), transfer the bottom layer toa cleanglass tube and extract it again with methylene chloride. Evaporate the bottom layer in a stream of nitrogen and reconstitute the residue in 25 tL of ethyl acetate. Inject 4 1zL into the injection port. With our apparatus, calculation was automatic with the integrator. Figure 1 shows chromatographs from a serum blank, a Serum blanks gave no interfering peaks except as described for blood collected in evacuated rubber-stoppered tubes containing tris(2-butoxyethyl)-phosphate as described below. were each analyzed in triplicate on three separate days. Additional samples to quantitate within and between-run precisions and analytical recoveries were included.
Results

Quinidine:
Plotting the quinidine concentration against the ratio of the integrated area of internal standard to that of Within-run precision (CV) was 3% (F = 2 mgIL, n = 20), 6.9% (F = 4 mg/L, n = 10), and 1.5% (F = 8 mg/L, n = 8); between-run precision for the same samples was 3.0% (n = 20), 7.0% (n = 9), and 2.8% (n = 9), respectively.
Procainamide:
Plotting the procamnamide concentration against the ratio of the areas of internal standard to procainamide yielded a slope of 0.85 (SD 0.01) and a y-intercept of -0.23 (SD 0.17) for three successive days, a standard error of the estimate of 0.27, and correlation coefficient of 0.99. Analytical recovery was 110 (SD 6) % at 2 mg/L (n = 3), 110 (SD 1) % at 8 mgIL (n = 3), and 108 (SD 4) % at 20 mg/L (n = 3). There was no interference with procainamide quantitation at 2, 8, or 20 mg/L in the presence of qumnidine (8 mg/L). Procainamide concentrations were falsely increased in the presence of N-acetylprocainamide by 5% of the N-acetylprocainamide concentration.
Because the two peaks elute at different times, this suggests a breakdown of N-acetylprocainamide to procainamide, thus giving a small interference in quantitating procainamide. Within-run precision was 7.7%
(1 = 4 mg/L, n = 14), 1.6% (1 = 8 mg/L, n = 16), and 2.3% (F = 12 mg/L, n = 12); at the same concentrations, between-run precision was 4.7% (n = 10), 3.3% (n = 20), and 1.9% (n = 10), respectively.
N-Acetylprocainamide:
Plotting the concentration vs the ratio of area of internal standard to area of N-acetylprocainamide for assays on three successive days gave a slope of 0.59 (SD 0.03) and a y-intercept of 0.28 (SD 0.17), a standard error of the estimate of 0.19, and a correlation coefficient of 0.99. Analytical recovery was 101 (SD 8) % at 5 mg/L (n = 6) and 113 (SD 4) % at 20 mgIL (n = 3). There was no interference with N-acetylprocainamide quantitation at 2, 10, or 20 mg/L in the presence of quinidine (8 mg/L) or procainamide (8 mg/L). Within-run precision was 6.3% (F = 5 mg/L, n = 6), 3.6% (F = 10 mg/L, n = 20), and 4.0% (F = 20 mg/L, n = 10).
Between-run
precision at the same concentration was, respectively, 9.3% (n = 6), 4.3% (n = 20), and 3.8% (n = 10).
Blood-collection methods:
Sera from blood collected in previously distributed
Vacutainer Tubes with rubber stoppers thatcontained the plasticizer tris(2-butoxyethyl)phosphate gave an early peak, which interfered with procainamide quantitation. Overestimation of integrated procainamide area led to subsequent overestimation of drug concentration. Table  1 compares results from our current method with an enzyme immunoassay method (EMIT-cad; Syva Co., Palo Alto, CA 94304) for five sera containing procainamide and N-acetylprocainamide.
Blood
Clinical data: The method described here has produced satisfactory results for us in general and in specialized clinical
andresearch settings, such as close follow-up of patients who have been resuscitated from prehospital cardiac arrest (13). In these patients "therapeutic" concentrations of the membrane-active antiarrhythmic agents procainamide or quinidine may protect against recurrence of cardiac arrest. Concentrations of these drugs in the blood of these patients are followed routinely and demonstrate a large degree of intra. and interindividual variability (Figure 2 ), underscoring the utility of periodic determinations of plasma drug concentrations.
We have also used this method to quantitate total and unbound quinidine in the determination of the free drug fraction (14).The mean unbound quinidine fraction was 8.1 (SD 3.2) %(n = 36) in outpatients with cardiac disease. Inpatients with cardiac diseasehad an mean unbound fractionof quinidine of 6.3 (SD 4.6) % (n = 101),procainamide 62.3 (SD 11.2)% (n = 92), and N-acetylprocainamide 70.0 (SD 14.4) % (n = 13).
We compared the present method with another standard clinical assay, to ascertain that the ranges of results were similar and that no bias existed that would influence the blood specimens with procainamide concentrations of 0.0 to 13.7 mgIL and associated N-acetylprocainamide values ranging from 0.0 to 14.7 mg/L were quantitated by both the current method and the EMIT assay method. The mean procainamide and the N-acetylprocainamide concentrations by our current method were 4.8 (SD 3.2) and 5.4 (SD 3.6) mg/L, respectively; by EMIT, these values were 4.9 (SD 3.0) and 5.4 (SD 3.4) mg/L, respectively. There was a significant correlation between results by the two methods (r = 0.95, p <0.01 for procainamide; r = 0.97, p <0.01 for N-acetylprocainamide), no bias in mean results, and random differences of individual determinations. Fifty additional patients' samples containing quinidine from 0.0 to 12.2 mgIL were quantitated by the current method and by spectrophotofluorometry (1). The mean concentration by the latter method was 2.8 (SD 2.1) mg/L, and by our method 2.7 (SD 2.4) mg/L (r = 0.96, p <0.01).
Interference by other compounds:
There was no interference with this assay technique by therapeutic concentrations 
Discussion
The only interference we detected is that of procainamide quantitation in the presence of N-acetylprocainamide. Blood collected in the older red-top tubes also have abnormalities in quinidine binding and quinidine quantitation because of displacement of the drug by the plasticizer (14, 17) . Furthermore, the two peaks may so perfectly merge as to escape notice, especially at lower sensitivity.
Use of the newer nitrogen-phosphorus detector to quantitate antiarrhythmic agents gave few problems, once we set up and used this method regularly. Early troubleshooting required the careful selection of voltages and attention to changing the collector to assure reproducible results.
We find this method clinically useful, having quantified both total and unbound drug concentrations in several hundred patients' samples. Procainamide and N-acetylprocainamide concentrations are quite similar to those obtained in our routine hospital laboratories by the EMIT system. 
Materials and Methods
We used a centrifugal analyzer that incorporates a spectrophotometer (Gemeni; Electro-Nucleonics, 
